502 related articles for article (PubMed ID: 29178444)
1. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab for multiple sclerosis.
Riera R; Porfírio GJ; Torloni MR
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M; Ridley B; Minozzi S; Del Giovane C; Peryer G; Piggott T; Foschi M; Filippini G; Tramacere I; Baldin E; Nonino F
Cochrane Database Syst Rev; 2024 Jan; 1(1):CD011381. PubMed ID: 38174776
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Tramacere I; Del Giovane C; Salanti G; D'Amico R; Filippini G
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD011381. PubMed ID: 26384035
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab for multiple sclerosis.
Riera R; Torloni MR; Martimbianco ALC; Pacheco RL
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD011203. PubMed ID: 37272540
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
7. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod for relapsing-remitting multiple sclerosis.
La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
[TBL] [Abstract][Full Text] [Related]
9. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
10. Ocrelizumab for multiple sclerosis.
Lin M; Zhang J; Zhang Y; Luo J; Shi S
Cochrane Database Syst Rev; 2022 May; 5(5):CD013247. PubMed ID: 35583174
[TBL] [Abstract][Full Text] [Related]
11. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
[TBL] [Abstract][Full Text] [Related]
15. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Sanford M; Lyseng-Williamson KA
Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
20. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]